ImmunityBio (IBRX) Jumps Ahead of Oncology Event

We recently published 10 Big Names With Effortless Double-Digit Gains. ImmunityBio Inc. (NASDAQ:IBRX) was one of the best performers on Monday.

ImmunityBio saw its share prices jump by 14.55 percent on Monday to finish at $6.93 apiece as investors loaded portfolios ahead of its participation in an event later this month by the American Society of Clinical Oncology (ASCO).

According to the company, it would participate in the three-day 2026 ASCO Genitourinary Cancers Symposium on February 26 and 28 at the Moscone West in San Francisco, California.

Held annually, the event focuses on the latest research and treatments for GU cancers, including prostate, bladder, kidney, and testicular cancer.

Meanwhile, investors will be watching out for developments about ImmunityBio Inc.’s (NASDAQ:IBRX) own cancer treatment, Anktiva.

Earlier this year, ImmunityBio Inc. (NASDAQ:IBRX) announced that it achieved a 700 percent sales jump from its therapy Anktiva, and that it would expand its operations into Saudi Arabia.

According to the company, it is set to begin selling Anktiva, in combination with an immune checkpoint inhibitor, for lung cancer patients in Saudi Arabia after securing the latter’s FDA approval.

Lung cancer is one of the most prevalent cancer types in Saudi.

While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.